ORIGINAL_ARTICLE
New Approaches to Use Nanoparticles for Treatment of Colorectal Cancer; a Brief Review
Nanoparticles have been at the center of research focus as a new promising material for the treatment of cancer in recent years. Although many chemotherapy drugs for cancer treatment are available, their potential toxicity is the main point of concern. On the other hand, the conventional chemotherapeutic approach has not been found to be very efficient in colorectal cancer (CRC) as the drug molecule does not reach the target site with an effective concentration. A major challenge in cancer therapy is to destroy tumor cells without harming the normal tissue. To overcome this problem scientists are trying to use nanoparticles to directly target cancer cells for a more effective treatment and reduced toxicity. Different nanoparticles such as: liposomes, polymeric nanoparticles, dendrimers, and silica have been developed to carry a variety of anticancer agents including: cytotoxic drugs, chemo modulators, siRNA and antiangiogenic agents. This review discusses various treatments for colon cancer and the potential use of nanoparticles which facilitate targeting of cancer cells. The outlook for new treatment strategies in CRC management is also underlined.
https://www.nanomedicine-rj.com/article_21866_f2cef3c4a5967b2b107c33a5b7cb9e98.pdf
2016-10-01
59
68
10.7508/nmrj.2016.02.001
nanoparticles
Colorectal cancer
Treatment
liposomes
Dendrimers
Drug delivery system
Leila
Hamzehzadeh
leila.hamzehzadeh64@gmail.com
1
Department of Medical Genetic, Faculty of Medicine, Mashhad University, Mashhad, Iran
AUTHOR
Armin
Imanparast
imanparasta931@mums.ac.ir
2
Department of Medical physics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Amir
Tajbakhsh
tajbakhsha921@mums.ac.ir
3
Department of Modern Sciences and Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Mahdi
Rezaee
rezaeem4@mums.ac.ir
4
Department of Medical Biotechnology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Alireza
Pasdar
pasdara@mums.ac.ir
5
Department of Medical Genetic, Faculty of Medicine, Mashhad University, Mashhad, Iran
LEAD_AUTHOR
1. Siegel R, DeSantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014;64(2):104-17.
1
2. Haggar F, Boushey R. Colorectal Cancer Epidemiology: Incidence, Mortality, Survival, and Risk Factors. Clin Colon Rectal Surg. 2009;22(04):191-7.
2
3. Chaurasia M, Chourasia MK, Jain NK, Jain A, Soni V, Gupta Y, et al. Cross-linked guar gum microspheres: A viable approach for improved delivery of anticancer drugs for the treatment of colorectal cancer. AAPS PharmSciTech. 2006;7(3):E143-E51.
3
4. Wilczewska AZ, Niemirowicz K, Markiewicz KH, Car H. Nanoparticles as drug delivery systems. Pharmacol Rep. 2012;64(5):1020-37.
4
5. Davis ME, Chen Z, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008;7(9):771-82.
5
6. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in Medicine: Therapeutic Applications and Developments. Clin Pharmacol Ther. 2007;83(5):761-9.
6
7. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751-60.
7
8. Shi M, Ho K, Keating A, Shoichet MS. Doxorubicin-Conjugated Immuno-Nanoparticles for Intracellular Anticancer Drug Delivery. Adv Funct Mater. 2009;19(11):1689-96.
8
9. Himanshu A, Sitasharan P, Singhai A. Liposomes as drug carriers. IJPLS. 2011;2(7):945-51.
9
10.Muhamad II, Selvakumaran S, Lazim NAM. Designing Polymeric Nanoparticles for Targeted Drug Delivery System. Nanomedicine. 2014;287:287.
10
11.Allemann E, Gurny R, Doelker E. Drug-loaded nanoparticles: preparation methods and drug targeting issues. Eur J Pharm Biopharm. 1993;39(5):173-91.
11
12.Patri AK, Majoros IJ, Baker JR. Dendritic polymer macromolecular carriers for drug delivery. Curr Opin Chem Biol. 2002;6(4):466-71.
12
13.Tripathy S, Das MK. Dendrimers and their Applications as Novel Drug Delivery Carriers. JAPS. 2013;3(9):142-9.
13
14.Nanjwade BK, Bechra HM, Derkar GK, Manvi FV, Nanjwade VK. Dendrimers: Emerging polymers for drug-delivery systems. Eur J Pharm Sci. 2009;38(3):185-96.
14
15.Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev. 2004;56(9):1257-72.
15
16.Slowing I, Viveroescoto J, Wu C, Lin V. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers.Adv Drug Deliv Rev. 2008;60(11):1278-88.
16
17.Vallet-Regà M. Nanostructured mesoporous silica matrices in nanomedicine. J Intern Med. 2010;267(1):22-43.
17
18.Liu S, Han M-Y. Silica-Coated Metal Nanoparticles. Chem Asian J. 2009:36-45.
18
19.Jaiswal M, Dudhe R, Sharma PK. Nanoemulsion: an advanced mode of drug delivery system. 3 Biotech. 2014;5(2):123-7.
19
20.Bouchemal K, Briançon S, Perrier E, Fessi H. Nano-emulsion formulation using spontaneous emulsification: solvent, oil and surfactant optimisation. Int J Pharm. 2004;280(1-2):241-51.
20
21.Kim C-K, Cho Y-J, Gao Z-G. Preparation and evaluation of biphenyl dimethyl dicarboxylate microemulsions for oral delivery. J Control Release. 2001;70(1-2):149-55.
21
22.Qadir A, Faiyazuddin MD, Talib Hussain MD, Alshammari TM, Shakeel F. Critical steps and energetics involved in a successful development of a stable nanoemulsion. J Mol Liq. 2016;214:7-18.
22
23.Gullotti E, Yeo Y. Extracellularly Activated Nanocarriers: A New Paradigm of Tumor Targeted Drug Delivery. Mol Pharmaceutics. 2009;6(4):1041-51.
23
24.Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, et al. Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. Proc Natl Acad Sci. 1998;95(8):4607-12.
24
25.Nishimori H, Kondoh M, Isoda K, Tsunoda S-i, Tsutsumi Y, Yagi K. Silica nanoparticles as hepatotoxicants. Eur J Pharm Biopharm. 2009;72(3):496-501.
25
26.Maeda H. Macromolecular therapeutics in cancer treatment: The EPR effect and beyond. J Control Release. 2012;164(2):138-44.
26
27.Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles. Mol Pharmaceutics. 2008;5(4):505-15.
27
28.Hume DA. The mononuclear phagocyte system. Curr Opin Immunol. 2006;18(1):49-53.
28
29.Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul. 2001;41(1):189-207.
29
30.Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol. 1965;13(1):238-IN27.
30
31.Abreu AS, Castanheira EMS, Queiroz M-JRP, Ferreira PMT, Vale-Silva LA, Pinto E. Nanoliposomes for encapsulation and delivery of the potential antitumoral methyl 6-methoxy-3-(4-methoxyphenyl)-1H-indole-2-carboxylate. Nanoscale Res Lett. 2011;6(1):482.
31
32.Silva R, Ferreira H, Cavaco-Paulo A. Sonoproduction of Liposomes and Protein Particles as Templates for Delivery Purposes. Biomacromolecules. 2011;12(10):3353-68.
32
33.Patil YP, Jadhav S. Novel methods for liposome preparation. Chem Phys Lipids. 2014;177:8-18.
33
34.Suntres ZE. Liposomal Antioxidants for Protection against Oxidant-Induced Damage. J Toxicol. 2011;2011:1-16.
34
35.Nag O, Awasthi V. Surface Engineering of Liposomes for Stealth Behavior. Pharmaceutics. 2013;5(4):542-69.
35
36.Noble GT, Stefanick JF, Ashley JD, Kiziltepe T, Bilgicer B. Ligand-targeted liposome design: challenges and fundamental considerations. Trends Biotechnol. 2014;32(1):32-45.
36
37.Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8(1):102.
37
38.Barenholz Y. Doxil® — The first FDA-approved nano-drug: Lessons learned. J Control Release. 2012;160(2):117-34.
38
39.Rivera E. Liposomal Anthracyclines in Metastatic Breast Cancer: Clinical Update. Oncologist. 2003;8(Supp-2):3-9.
39
40.Allen TM, Cullis PR. Liposomal drug delivery systems: From concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36-48.
40
41.Lam R, Ho D. Nanodiamonds as vehicles for systemic and localized drug delivery. Expert Opin Drug Deliv. 2009;6(9):883-95.
41
42.Lammers T, Hennink WE, Storm G. Tumour-targeted nanomedicines: principles and practice. Br J Cancer, BJC. 2008;99(3):392-7.
42
43.Li W, Chen H, Yu M, Fang J. Targeted Delivery of Doxorubicin Using a Colorectal Cancer-Specific ssDNA Aptamer. Anat Rec. 2014;297(12):2280-8.
43
44.Stang J, Haynes M, Carson P, Moghaddam M. A Preclinical System Prototype for Focused Microwave Thermal Therapy of the Breast. IEEE T Bio-Med Eng. 2012;59(9):2431-8.
44
45.Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE, et al. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics. 2011;21(7):440.
45
46.Gidding CEM, Kellie SJ, Kamps WA, de Graaf SSN. Vincristine revisited. Crit Rev Oncol Hematol. 1999;29(3):267-87.
46
47.Celsion. Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC) (ABLATE). In: ClinicalTrials.gov [Internet] [updated March 4, 2016; cited November 1, 2011]. Available from:https://clinicaltrials.gov/ct2/show/NCT01464593
47
48.Bilensoy E, Sarisozen C, Esendağlı G, Doğan AL, Aktaş Y, Şen M, et al. Intravesical cationic nanoparticles of chitosan and polycaprolactone for the delivery of Mitomycin C to bladder tumors. Int J Pharm. 2009;371(1-2):170-6.
48
49.Torchilin V. Multifunctional pharmaceutical nanocarriers. New York: Springer Science & Business Media; 2008.
49
50.Zhang L, Radovic-Moreno AF, Alexis F, Gu FX, Basto PA, Bagalkot V, et al. Co-Delivery of Hydrophobic and Hydrophilic Drugs from Nanoparticle–Aptamer Bioconjugates. ChemMedChem. 2007;2(9):1268-71.
50
51.Subudhi M, Jain A, Jain A, Hurkat P, Shilpi S, Gulbake A, et al. Eudragit S100 Coated Citrus Pectin Nanoparticles for Colon Targeting of 5-Fluorouracil. Materials. 2015;8(3):832-49.
51
52.Tummala S, Satish Kumar MN, Prakash A. Formulation and characterization of 5-Fluorouracil enteric coated nanoparticles for sustained and localized release in treating colorectal cancer. Saudi Pharm J. 2015;23(3):308-14.
52
53.Asghar LFA, Chandran S. Design and evaluation of matrices of Eudragit with polycarbophil and carbopol for colon-specific delivery. J Drug Target. 2008;16(10):741-57.
53
54.Obeidat WM, Price JC. Preparation and evaluation of Eudragit S 100 microspheres as pH-sensitive release preparations for piroxicam and theophylline using the emulsion-solvent evaporation method. J Microencapsul. 2006;23(2):195-202.
54
55.Leclere L, Cutsem PV, Michiels C. Anti-cancer activities of pH- or heat-modified pectin. Front Pharmacol. 2013;4.
55
56. US National Institute of Health. ClinicalTrial.gov [website]. USA [updated 11/9/2016]. Available from: https://clinicaltrials.gov/.
56
57.Xiao B, Zhang M, Viennois E, Zhang Y, Wei N, Baker MT, et al. Inhibition of MDR1 gene expression and enhancing cellular uptake for effective colon cancer treatment using dual-surface-functionalized nanoparticles. Biomaterials. 2015;48:147-60.
57
58.Semwal R, Semwal D, Madan A, Paul P, Mujaffer F, Badoni R. Dendrimers: A novel approach for drug targeting. J Pharm Res. 2010;3:2238-47.
58
59.Tomalia DA, Baker H, Dewald J, Hall M, Kallos G, Martin S, et al. A New Class of Polymers: Starburst-Dendritic Macromolecules. Polym J. 1985;17(1):117-32.
59
60.Bhadra D, Bhadra S, Jain S, Jain NK. A PEGylated dendritic nanoparticulate carrier of fluorouracil. Int J Pharm. 2003;257(1-2):111-24.
60
61.Xu Q, Wang C-H, Wayne Pack D. Polymeric Carriers for Gene Delivery: Chitosan and Poly(amidoamine) Dendrimers. Curr Pharm Des. 2010;16(21):2350-68.
61
62.Mignani S, Majoral JP. Dendrimers as macromolecular tools to tackle from colon to brain tumor types: a concise overview. New J Chem. 2013;37(11):3337.
62
63.Amato G. Silica-Encapsulated Efficient and Stable Si Quantum Dots with High Biocompatibility. Nanoscale Res Lett. 2010;5(7):1156-60.
63
64.Wei L, Hu N, Zhang Y. Synthesis of Polymer—Mesoporous Silica Nanocomposites. Materials. 2010;3(7):4066-79.
64
65.Bharti C, Gulati N, Nagaich U, Pal A. Mesoporous silica nanoparticles in target drug delivery system: A review. Int J Pharma Investig. 2015;5(3):124.
65
66.Radhakrishnan K, Gupta S, Gnanadhas DP, Ramamurthy PC, Chakravortty D, Raichur AM. Protamine-Capped Mesoporous Silica Nanoparticles for Biologically Triggered Drug Release. Part Part Syst Char. 2013;31(4):449-58.
66
67.Yu M, Jambhrunkar S, Thorn P, Chen J, Gu W, Yu C. Hyaluronic acid modified mesoporous silica nanoparticles for targeted drug delivery to CD44-overexpressing cancer cells. Nanoscale. 2013;5(1):178-83.
67
68.Hanafi-Bojd MY, Jaafari MR, Ramezanian N, Xue M, Amin M, Shahtahmassebi N, et al. Surface functionalized mesoporous silica nanoparticles as an effective carrier for epirubicin delivery to cancer cells. Eur J Pharm Biopharm. 2015;89:248-58.
68
69.Chen B-H, Huang R-FS, Wei Y-J, Stephen Inbaraj B. Inhibition of colon cancer cell growth by nanoemulsion carrying gold nanoparticles and lycopene. Int J Nanomedicine. 2015;10(1):2823-46.
69
70.Zhou HS, Sasahara H, Honma I, Komiyama H, Haus JW. Coated Semiconductor Nanoparticles: The CdS/PbS System's Photoluminescence Properties. Chem Mater. 1994;6(9):1534-41.
70
71.Ghosh Chaudhuri R, Paria S. Core/Shell Nanoparticles: Classes, Properties, Synthesis Mechanisms, Characterization, and Applications. Chem Rev. 2012;112(4):2373-433.
71
72.Kalele S, Gosavi S, Urban J, Kulkarni S. Nanoshell particles: synthesis, properties and applications. Curr Sci. 2006;91(8):1038-52.
72
73.Bai Y, Teng B, Chen S, Chang Y, Li Z. Preparation of Magnetite Nanoparticles Coated with an Amphiphilic Block Copolymer: A Potential Drug Carrier with a Core-Shell-Corona Structure for Hydrophobic Drug Delivery. Macromol Rapid Commun. 2006;27(24):2107-12.
73
74.Sounderya N, Zhang Y. Use of Core/Shell Structured Nanoparticles for Biomedical Applications. Recent Pat Biomed Eng. 2008;1(1):34-42.
74
75.Stanciu L, Won Y-H, Ganesana M, Andreescu S. Magnetic Particle-Based Hybrid Platforms for Bioanalytical Sensors. Sensors. 2009;9(4):2976-99.
75
76.Ma Y, Coombes AGA. Designing colon-specific delivery systems for anticancer drug-loaded nanoparticles: An evaluation of alginate carriers. J Biomed Mater Res A. 2013;102(9):3167-76.
76
77.Anitha A, Deepa N, Chennazhi KP, Lakshmanan V-K, Jayakumar R. Combinatorial anticancer effects of curcumin and 5-fluorouracil loaded thiolated chitosan nanoparticles towards colon cancer treatment. BBA-Gen Subjects. 2014;1840(9):2730-43.
77
78.Prajakta D, Ratnesh J, Chandan K, Suresh S, Grace S, Meera V, et al. Curcumin Loaded pH-Sensitive Nanoparticles for the Treatment of Colon Cancer. J Biomed Nanotechnol. 2009;5(5):445-55.
78
ORIGINAL_ARTICLE
A First-Principles Study of the Interaction of Aspirin with Nitrogen-Doped TiO2 Anatase Nanoparticles
Objective(s): First-principles calculations have been carried out to investigate the interaction of aspirin molecule with nitrogen-doped TiO2 anatase nanoparticles using the density functional theory method in order to fully exploit the biosensing capabilities of TiO2 particles. Methods: For this purpose, we have mainly studied the adsorption of the aspirin molecule on the fivefold coordinated titanium atom site of the TiO2 nanoparticles because of the more reactivity of this site in comparison with the other sits. The complex systems consisting of the aspirin molecule positioned toward the undoped and nitrogen-doped nanoparticles have been relaxed geometrically. Results: The obtained results include structural parameters such as bond lengths and energetic of the systems. The electronic structure and its variations resulting from the adsorption process, including the density of states, molecular orbitals and the Mulliken charge transfer analysis have been discussed. We found that the adsorption of aspirin molecule on the nitrogen-doped TiO2 nanoparticles is energetically more favorable than the adsorption on the undoped ones. Conclusions: These results thus provide a theoretical basis and overall understanding on the interaction of TiO2 nanoparticles with aspirin molecule for applications in modeling of efficient nanomedicine carriers, biosensors and drug delivery purposes.
https://www.nanomedicine-rj.com/article_20620_60a0ed25b51fbdda637f87fc3bc46a74.pdf
2016-10-01
69
78
10.7508/nmrj.2016.02.002
TiO2
Anatase nanoparticle
Adsorption
aspirin
DFT
PDOS
Amirali
Abbasi
a_abbasi@azaruniv.edu
1
Molecular Simulation laboratory (MSL), Azarbaijan Shahid Madani University, Tabriz, Iran
LEAD_AUTHOR
Jaber
Jahanbin Sardroodi
jsardroodi@azaruniv.edu
2
Molecular Simulation laboratory (MSL), Azarbaijan Shahid Madani University, Tabriz, Iran
AUTHOR
1. Linsebigler AL, Lu G, Yates Jr JT. Photocatalysis on TiO2 surfaces: principles, mechanisms, and selected results. Chem Rev. 1995;95(3):735-58.
1
2. Diebold U. The surface science of titanium dioxide. Surface science reports. 2003;48(5):53-229.
2
3. Fujishima A, Zhang X, Tryk DA. TiO2 photocatalysis and related surface phenomena. Surf Sci Rep. 2008;63(12):515-82.
3
4. Henderson MA. A surface science perspective on photocatalysis. Surf Sci Rep. 2011;66(6):185-297.
4
5. Banfield JF, Veblen DR. Conversion of perovskite to anatase and TiO2 (B): A TEM study and the use of fundamental building blocks for understanding relationships among the TiO2 minerals. Am Mineral. 1992;77(5-6):545-57.
5
6. Grätzel M. Photoelectrochemical cells. Nature. 2001;414(6861):338-44.
6
7. Fujishima A. Electrochemical photolysis of water at a semiconductor electrode. Nature. 1972;238:37-8.
7
8. Dutta PK, Ginwalla A, Hogg B, Patton BR, Chwieroth B, Liang Z, et al. Interaction of carbon monoxide with anatase surfaces at high temperatures: optimization of a carbon monoxide sensor. J Phys Chem B. 1999;103(21):4412-22.
8
9. Garfunkel E, Gusev E, editors. Fundamental Aspects of Ultrathin Dielectrics on Si-based Devices. Netherlands: Springer Science & Business Media; 2012.
9
10.Liu H, Zhao M, Lei Y, Pan C, Xiao W. Formaldehyde on TiO2 anatase (101): A DFT study. Comput Mater Sci. 2012;51(1):389-95.
10
11.Erdogan R, Ozbek O, Onal I. A periodic DFT study of water and ammonia adsorption on anatase TiO2 (001) slab. Surf Sci. 2010;604(11):1029-33.
11
12.Onal I, Soyer S, Senkan S. Adsorption of water and ammonia on TiO2-anatase cluster models. Surf Sci. 2006;600(12):2457-69.
12
13.Wei Z, Mei W, Xiyu S, Yachao W, Zhenyong L. Electronic and optical properties of the doped TiO2 system. J Semicond. 2010;31(7):072001.
13
14.Liu J, Dong L, Guo W, Liang T, Lai W. CO adsorption and oxidation on N-doped TiO2 nanoparticles. J Phys Chem C. 2013;117(25):13037-44.
14
15.Zhao D, Huang X, Tian B, Zhou S, Li Y, Du Z. The effect of electronegative difference on the electronic structure and visible light photocatalytic activity of N-doped anatase TiO2 by first-principles calculations. Appl Phys Lett. 2011;98(16):162107.
15
16.Tang S, Cao Z. Adsorption of nitrogen oxides on graphene and graphene oxides: insights from density functional calculations. J Chem Phys. 2011;134(4):044710.
16
17.Rumaiz AK, Woicik JC, Cockayne E, Lin HY, Jaffari GH, Shah SI. Oxygen vacancies in N doped anatase TiO2: Experiment and first-principles calculations. Appl Phys Lett. 2009;95(26):262111.18.Chen Q, Tang C, Zheng G. First-principles study of TiO2 anatase (101) surfaces doped with N. Physica B Condens Matter. 2009;404(8):1074-8.
17
19.Jia L, Wu C, Li Y, Han S, Li Z, Chi B, et al. Enhanced visible-light photocatalytic activity of anatase TiO2 through N and S codoping. Appl Phys Lett. 2011;98(21):211903.
18
20.Liu J, Liu Q, Fang P, Pan C, Xiao W. First principles study of the adsorption of a NO molecule on N-doped anatase nanoparticles. Appl Surf Sci. 2012;258(20):8312-8.
19
21.Li Y-F, Aschauer U, Chen J, Selloni A. Adsorption and reactions of O2 on anatase TiO2. Acc Chem Res. 2014;47(11):3361-8.
20
22.Berger T, Sterrer M, Diwald O, Knözinger E, Panayotov D, Thompson TL, et al. Light-induced charge separation in anatase TiO2 particles. J Phys Chem B. 2005;109(13):6061-8.
21
23.Mirzaei M, Ahadi H, Shariaty-Niassar M, Akbari M. Fabrication and Characterization of Visible Light active Fe-TiO2 Nanocomposites as Nanophotocatalyst. Int J Nanosci Nanotechnol. 2015;11(4):289-93.
22
24.Zarei H, Zeinali M, Ghourchian H, Eskandari K. Gold nano-particles as electrochemical signal amplifier for immune-reaction monitoring. Int J Nano Dimens. 2013;4(1):69.
23
25.Zuas O, Budiman H, Hamim N. Anatase TiO2 and mixed M-Anatase TiO2 (M= CeO2 or ZrO2) nano powder: Synthesis and characterization. Int J Nano Dimens. 2013;4(1):7.
24
26.Otoufi M, Shahtahmasebebi N, Kompany A, Goharshadi E. A systematic growth of Gold nanoseeds on Silica for Silica@ Gold core-shell nanoparticles and investigation of optical properties. Int J Nano Dimens. 2014;5(6):525.
25
27.Rastkar Ebrahimzadeh A, Abbasi M, Jahanbin Sardroodi J, Afshari S. Density functional theory study of the adsorption of NO2 molecule on Nitrogen-doped TiO2 anatase nanoparticles. Int J Nano Dimens. 2014;6:11-7.
26
28.Sardroodi JJ, Afshari S, Ebrahimzadeh AR, Abbasi M. Theoretical computation of the quantum transport of zigzag mono-layer Graphenes with various z-direction widths Int J Nano Dimens. 2015;6(1):105.
27
29.Abbasi A, Nadimi E, Plänitz P, Radehaus C. Density functional study of the adsorption of aspirin on the hydroxylated (001) α-quartz surface. Surf Sci. 2009;603(16):2502-6.
28
30.Hohenberg P, Kohn W. Inhomogeneous electron gas. Physical review. 1964;136(3B):B864.
29
31.Kohn W, Sham LJ. Self-consistent equations including exchange and correlation effects. PhysRev. 1965;140(4A):A1133.
30
32.Ozaki T, Kino H, Yu J, Han MJ, Kobayashi N, Ohfuti M et al (2011) The code, OpenMX, pseudo-atomic basis functions, and pseudopotentials is available as user manual on a web site: http://www.openmx-square.org/
31
33.Ozaki T. Variationally optimized atomic orbitals for large-scale electronic structures. Phys Rev B. 2003;67(15):155108.
32
34.Perdew JP, Burke K, Ernzerhof M. Generalized gradient approximation made simple. Phys Rev lett. 1996;77(18):3865.
33
35.Kokalj A. Computer graphics and graphical user interfaces as tools in simulations of matter at the atomic scale. Comput Mater Sci. 2003;28(2):155-68.
34
36. Available from: http://rruff.geo.arizona.edu/AMS/amcsd.php.
35
37.Wyckoff RWG, Wyckoff RW. Crystal structures: Interscience New York; 1960.
36
ORIGINAL_ARTICLE
Preparation and Characterization of Nanostructure Akermanite Powder by Mechanical Activation Method
Objective(s): So far, extensive research has been conducted on the preparation and characterization of nano ceramics based on Ca-Si by sol- gel method and bioactivity was evaluated, but, a few researches have paid attention to the preparation of materials by mechanical activation (MA). The aim of this study was the preparation of akermanite nano powder by mechanical activation method and bioactivity evaluation. Methods: Akermanite was prepared by MA method and subsequent heat treatment. Samples were mixed of calcium oxide (CaO), silicon dioxide (SiO2) and magnesium oxide (MgO) with molar ratio of 2:2:1, respectively. These were milled for 6 h, 8 h, and 10 h with ball-to- powder ratio 10:1 and rotation speed of 300 rpm. After synthesis, the samples were pressed under 25 MPa and heated at 1100 ºC for 3 h. X-ray diffraction (XRD), transmission electron microscopy (TEM) and energy-dispersive x-ray spectrum (EDX-mapping) analysis were performed to characterize three kinds of powder. Bioactivity evaluation of the akermanite ceramics was investigated by being immersed in the simulated body fluid (SBF). Results: According to XRD pattern, the sample which was milled for 10 h at heat treatment at 1100 ºC only indicated the pure akermanite phase. The crystalline size of nano powder indicated that with ball milling time increase, the sizes of crystalline were decreased. Also, SEM images showed that, apatite nucleation happened and it grew on the sample surface. Conclusions: In the present investigation, the nanostructure akermanite powder can be prepared by mechanical activation (MA).
https://www.nanomedicine-rj.com/article_20911_e8f4f1651c99b1c012a9effcce6260aa.pdf
2016-10-01
79
83
10.7508/nmrj.2016.02.003
Mechanical activation
Akermanite
Nano powder
kazem
Marzban
kazemmarzban@yahoo.com
1
Department of biomaterials, Science and Research Branch, Islamic Azad University, Yazd, Iran
LEAD_AUTHOR
1.Liu Q, Cen L, Yin S, Chen L, Liu G, Chang J, et al. A comparative study of proliferation and osteogenic differentiation of adipose-derived stem cells on akermanite and β-TCP ceramics. Biomaterials. 2008;29(36):4792-9.
1
2.Mohammadi H, Hafezi M, Nezafati N, Heasarki S, Nadernezhad A, Ghazanfari S, et al. Bioinorganics in bioactive calcium silicate ceramics for bone tissue repair: bioactivity and biological properties. J Ceram Sci Technol. 2014;5(1):1-12.
2
3.Srivastava AK, Pyare R. Characterization of CuO substituted 45S5 bioactive glasses and glass-ceramics. Int J Sci Technol Res. 2012;1:28-41.
3
4.Mirhadi S, Tavangarian F, Emadi R. Synthesis, characterization and formation mechanism of single-phase nanostructure bredigite powder. Mater Sci Eng C. 2012;32(2):133-9.
4
5.Liu G, Wu C, Fan W, Miao X, Sin DC, Crawford R, et al. The effects of bioactive akermanite on physiochemical, drug‐delivery, and biological properties of poly (lactide‐co‐glycolide) beads. J Biomed Mater Res B Appl Biomater. 2011;96(2):360-8.
5
6.Cabrera A, Mendoza M. Lamellar ceramics of Ca2SiO4 prepared by mechanical activation of powders. Rev Mex Fis. 2006;52(4):346-51.
6
7.Fathi MH, Zahrani EM. The effect of rotation speed and time of milling on synthesis and properties of fluoridated hydroxyapatite biomaterial. Iran J Pharm Sci. 2008;4(3):201-8.
7
8.Wu C, Chang J. A novel akermanite bioceramic: preparation and characteristics. J Biomater Appl. 2006;21(2):119-29.
8
9.Maleki-Ghaleh H, Hafezi M, Hadipour M, Nadernezhad A, Aghaie E, Behnamian Y, et al. Effect of Tricalcium Magnesium Silicate Coating on the Electrochemical and Biological Behavior of Ti-6Al-4V Alloys. PloS one. 2015;10(9):e0138454.
9
10.Mihailova I, Radev L, Aleksandrova V, Colova I, Salvado I, Fernandes M. Novel merwinite/akermanite ceramics: in vitro bioactivity. Bulg Chem Commun. 2015;47(1):253-60.
10
11.Razavi M, Fathi M, Savabi O, Razavi SM, Beni BH, Vashaee D, et al. Controlling the degradation rate of bioactive magnesium implants by electrophoretic deposition of akermanite coating. Ceram Int. 2014;40(3):3865-72.
11
12.Ramaswamy Y, Wu C, Zhou H, Zreiqat H. Biological response of human bone cells to zinc-modified Ca–Si-based ceramics. Acta Biomater. 2008;4(5):1487-97.
12
13. Wang G, Lu Z, Liu X, Zhou X, Ding C, Zreiqat H. Nanostructured glass–ceramic coatings for orthopaedic applications. J R Soc Interface. 2011;8(61):1192.
13
14.Wu C, Ramaswamy Y, Gale D, Yang W, Xiao K, Zhang L, et al. Novel sphene coatings on Ti–6Al–4V for orthopedic implants using sol–gel method. Acta Biomate. 2008;4(3):569-76.
14
15.Wu C, Ramaswamy Y, Liu X, Wang G, Zreiqat H. Plasma-sprayed CaTiSiO5 ceramic coating on Ti-6Al-4V with excellent bonding strength, stability and cellular bioactivity. J R Soc Interface. 2009;6(31):159-68.
15
16.Ramaswamy Y, Wu C, Dunstan CR, Hewson B, Eindorf T, Anderson GI, et al. Sphene ceramics for orthopedic coating applications: An in vitro and in vivo study. Acta biomater. 2009;5(8):3192-204.
16
17.Hou X, Yin G, Chen X, Liao X, Yao Y, Huang Z. Effect of akermanite morphology on precipitation of bone-like apatite. Appl Surf Sci. 2011;257(8):3417-22.
17
18.Kokubo T. Bioactive glass ceramics: properties and applications. Biomaterials. 1991;12(2):155-63.
18
19.Ventura J, Tulyaganov D, Agathopoulos S, Ferreira J. Sintering and crystallization of akermanite-based glass–ceramics. Mater Lett. 2006;60(12):1488-91.
19
20.Gheisari H, Karamian E. Preparation and characterization of hydroxyapatite reinforced with hardystonite as a novel bio-nanocomposite for tissue engineering. Nanomed J. 2015;2(2):141-52.
20
21.Gough JE, Jones JR, Hench LL. Nodule formation and mineralisation of human primary osteoblasts cultured on a porous bioactive glass scaffold. Biomaterials. 2004;25(11):2039-46.
21
ORIGINAL_ARTICLE
The Impact of Nano-Sized Gold Particles on the Target Dose Enhancement Based on Photon Beams Using by Monte Carlo Method
Objective(s): In this study we evaluate the impact of the different aspects of Gold Nano-Particles (GNPs) on the target absorptive Dose Enhancement Factor (DEF) during external targeted radiotherapy with photon beams ranging from kilovolt to megavolt energies using Monte Carlo simulation. Methods: We have simulated the interaction of photon beams with various energies of radiation using water solution containing GNPs to be located in a tumor region and used MCNP5 code for Initially, the water phantom in which a tumor dimensions of 1 × 1 × 1 cm3 was defined as the target, contained simulated GNPs. Then, themacroscopic DEF of GNPs of different sizes, including 15, 50, and 100 nm, had been calculated at the target area with a fixed concentration of 7 mg/g during external beam radiotherapy with single-energy photon beams ranging from keV to MeV. Results: The tumor DEFs in the presence of GNPs were obtained 1.69-2.66and 1.08-1.10 for keV and MeV beams, respectively. The highest DEF was achieved by photon energy of 50 keV. By increasing the size of the GNPs, the tumor dose factor raised too. Conclusions: The factors calculated for enhancing the target dose of GNPs were in good agreements with previous studies based on keV photon energies. For MeV photon energies, after a reduction in the boundary between the two areas of water and the solution containing GNPs, the dose factor was enhanced to its maximum value for 2 and 6 MeV photon beams at the depths of 2.6 and 5.6 cm, respectively.
https://www.nanomedicine-rj.com/article_21139_a90c0f9ba02427ddd299834406566296.pdf
2016-10-01
84
89
10.7508/nmrj.2016.02.004
Radiotherapy
Gold Nanoparticles (GNPs)
Dose Enhancement Factor (DEF)
Monte Carlo method
Radiation dosimetry
Hossein
Khosravi
hkhosravi55@gmail.com
1
Health Institute, Chmran Hospital, Tehran, Iran.
LEAD_AUTHOR
Armita
Mahdavi
armitamahdavi61@gmail.com
2
Deparment of Basic and Clinical Research, Tehran Heart Center, Tehran University of Medical Sciences
AUTHOR
Faezeh
Rahmani
faezeh.rahmani@gmail.com
3
Department of Physics, K. N. Toosi University of Technology, Tehran, Iran.
AUTHOR
Ahmad
Ebadi
gasabeh47@gmail.com
4
Health Institute, Chamran Hospital, Tehran, Iran
AUTHOR
1.Hainfeld JF, Slatkin DN, Smilowitz HM. The use of gold nanoparticles to enhance radiotherapy in mice. Phys Med Biol. 2004;49(18):N309.
1
2.Yih TC, Wei C. Nanomedicine in cancer treatment. Nanomed Nanotech Biol Med. 2005;1(2):191-2.
2
3.Kawasaki ES, Player A. Nanotechnology, nanomedicine, and the development of new, effective therapies for cancer. Nanomed Nanotech Biol Med. 2005;1(2):101-9.
3
4.Van den Heuvel F, Locquet J-P, Nuyts S. Beam energy considerations for gold nano-particle enhanced radiation treatment. Phys Med Biol. 2010;55(16):4509.
4
5.Butterworth KT, Coulter J, Jain S, Forker J, McMahon S, Schettino G, et al. Evaluation of cytotoxicity and radiation enhancement using 1.9 nm gold particles: potential application for cancer therapy. Nanotechnology. 2010;21(29):295101.
5
6.Toossi MTB, Ghorbani M, Mehrpouyan M, Akbari F, Sabet LS, Meigooni AS. A Monte Carlo study on tissue dose enhancement in brachytherapy: a comparison between gadolinium and gold nanoparticles. Australas Phys Eng Sci Med. 2012;35(2):177-85.
6
7.Coulter JA, Jain S, Butterworth KT, Taggart LE, Dickson GR, McMahon SJ, et al. Cell type-dependent uptake, localization, and cytotoxicity of 1.9 nm gold nanoparticles. Int J Nanomedicine. 2012;7(1).
7
8.Jain S, Hirst D, O'sullivan J. Gold nanoparticles as novel agents for cancer therapy. Br J Radiol. 2012;85(1010):101-13
8
9.Cruje C, Chithrani B. Integration of peptides for enhanced uptake of PEGylayed gold nanoparticles. J Nanosci Nanotechnol. 2015;15(3):2125-31.
9
10.Hirsch LR, Stafford R, Bankson J, Sershen S, Rivera B, Price R, et al. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci. 2003;100(23):13549-54.
10
11.Berbeco RI, Korideck H, Kumar R, Sridhar S, Detappe A, Ngwa W, et al. Targeted Gold Nanoparticles as Vascular Disrupting Agents During Radiation Therapy. Int J Radiat Oncol Biol Phys. 2014;90(1):S198.
11
12.Wolfe T, Chatterjee D, Lee J, Grant JD, Bhattarai S, Tailor R, et al. Targeted gold nanoparticles enhance sensitization of prostate tumors to megavoltage radiation therapy in vivo. Nanomed Nanotech Biol Med. 2015;11(5):1277-83.
12
13.Rengan AK, Bukhari AB, Pradhan A, Malhotra R, Banerjee R, Srivastava R, et al. In vivo analysis of biodegradable liposome gold nanoparticles as efficient agents for photothermal therapy of cancer. Nano lett. 2015;15(2):842-8.
13
14.Loo C, Lowery A, Halas N, West J, Drezek R. Immunotargeted nanoshells for integrated cancer imaging and therapy. Nano lett. 2005;5(4):709-11.
14
15.Jain S, Coulter JA, Hounsell AR, Butterworth KT, McMahon SJ, Hyland WB, et al. Cell-specific radiosensitization by gold nanoparticles at megavoltage radiation energies. Int J Radiat Oncol Biol Phys. 2011;79(2):531-9.
15
16.Zhang X-D, Wu D, Shen X, Chen J, Sun Y-M, Liu P-X, et al. Size-dependent radiosensitization of PEG-coated gold nanoparticles for cancer radiation therapy. Biomaterials. 2012;33(27):6408-19.
16
17.Ngwa W, Korideck H, Kassis AI, Kumar R, Sridhar S, Makrigiorgos GM, et al. In vitro radiosensitization by gold nanoparticles during continuous low-dose-rate gamma irradiation with I-125 brachytherapy seeds. Nanomed Nanotech Biol Med. 2013;9(1):25-7.
17
18.Cho SH. Estimation of tumour dose enhancement due to gold nanoparticles during typical radiation treatments: a preliminary Monte Carlo study. Phys Med Biol. 2005;50(15):N163-73.
18
19.Zhang SX, Gao J, Buchholz TA, Wang Z, Salehpour MR, Drezek RA, et al. Quantifying tumor-selective radiation dose enhancements using gold nanoparticles: a monte carlo simulation study. Biomed Microdevices. 2009;11(4):925-33.
19
20.Cho SH, Jones BL, Krishnan S. The dosimetric feasibility of gold nanoparticle-aided radiation therapy (GNRT) via brachytherapy using low-energy gamma-/x-ray sources. Phys Med Biol. 2009;54(16):4889.
20
21.Leung MKK, Chow JCL, Chithrani BD, Lee MJG, Oms B, Jaffray DA. Irradiation of gold nanoparticles by x-rays: Monte Carlo simulation of dose enhancements and the spatial properties of the secondary electrons production. Med Phys. 2011;38(2):624-31.
21
22.Lechtman E, Mashouf S, Chattopadhyay N, Keller BM, Lai P, Cai Z, et al. A Monte Carlo-based model of gold nanoparticle radiosensitization accounting for increased radiobiological effectiveness. Phys Med Biol. 2013;58(10):3075.
22
23.Koger B, Kirkby C. Sci—Thur AM: YIS-04: Gold Nanoparticle Enhanced Arc Radiotherapy: A Monte Carlo Feasibility Study. Med Phys. 2014;41(8):1-2.
23
24.Khan FM, Gibbons JP. Khan's the physics of radiation therapy: Lippincott Williams & Wilkins; 2014.
24
25.Gasiorowicz S. Quantum physics. Hoboken, NJ: John Wiley & Sons; 2007.
25
26.Esteve F, Corde S, Elleaume H, Adam JF, Joubert A, Charvet AM, et al. Enhanced radio sensitivity with iodinated contrast agents using monochromatic synchrotron X-rays on human cancerous cells. Acad Radiol. 2002;9(2):S540-S3.
26
27.Corde S, Joubert A, Adam JF, Charvet AM, Le Bas JF, Esteve F, et al. Synchrotron radiation-based experimental determination of the optimal energy for cell radiotoxicity enhancement following photoelectric effect on stable iodinated compounds. Br J Cancer. 2004;91(3):544-51.
27
28.Almond PR, Biggs PJ, Coursey BM, Hanson WF, Huq MS, Nath R, et al. AAPM American Association of Physicists in Medicine, Task Group 51: Protocol for clinical reference dosimetry of high-energy photon and electron beams. Med Phys. 1999;26:1847-70.
28
29.AGENCY IAE. Implementation of the International Code of Practice on Dosimetry in Radiotherapy (TRS 398): Review of Testing Results. Vienna: INTERNATIONAL ATOMIC ENERGY AGENCY; 2010.
29
30.Kiedrowski B, Brown F, Bull J. MCNP5-1.6, Feature Enhancements and Manual Clarifications. LA-UR-l0-06217. 2010.
30
31.Greening JR. Fundamentals of radiation dosimetry: CRC Press; 1985.
31
ORIGINAL_ARTICLE
Mathematical Kinetic Modeling on Isoniazid Release from Dex-HEMA-PNIPAAm Nanogels
Objective(s): The quantitative calculation of release data is more facil when mathematics come to help. mathematically modeling could aid optimizing and amending the delivery systems design. Aim of this study is to find out the isoniazid release kinetic. Methods: In this work degradable temperature sensitive dextran-hydroxy ethyl methacrylate- poly-N-isopropyl acryl amide (Dex-HEMA-PNIPAAm) nanogels which were synthesized by UV polymerization were loaded by Isoniazid. The Isoniazid release amounts taken from in vitro studies at two different temperatures, below and upper lower criticalsolution temperature (LCST) were mathematically modeled to investigate the kinetic of drug release. Mathematically inquiry of release phenomenon of Isoniazid makes it easy to predict and recognize the influence of delivery device laying out parameters on release kinetic formulation. The modeling was performed using model dependent methods, such as zero order, first order, Higuchi, Korsmeyer- Pepas, Hixon and Crowel. Results: The best fitted model showing the highest determination coefficient (R2) was Korsmeyer-Pepas which means predominant release mechanism is controlled by diffusion. Conclusions: The Isoniazid release pattern of most samples was combination of swelling, diffusion and degradation.
https://www.nanomedicine-rj.com/article_21159_ef299cad41a53e6849388eb12b6f632c.pdf
2016-10-01
90
96
10.7508/nmrj.2016.02.005
Release kinetic
Modeling
Zero order
First order
Higuchi
Maryam
Jafari
maryamjafari659@gmail.com
1
Chemical engineering department, Engineering faculty, University of Tehran, Tehran, Iran
AUTHOR
Babak
Kaffashi
kaffashi@ut.ac.ir
2
Chemical engineering department, Engineering faculty, University of Tehran, Tehran, Iran
LEAD_AUTHOR
1.Langer R, Chasin M. Biodegradable polymers as drug delivery system. New York:Marcel Dekker; 1990. p.71–120.
1
2. Papazoglou ES, Parthasarathy A. BioNanotechnology. Synthesis Lectures on Biomedical Engineering. 2007;2(1):1-139.
2
3.Shargel L, Yu ABC. Biopharmaceutics. Encyclopedia of Clinical Pharmacy: Informa Healthcare; 2002. p. 82-102.
3
4.Park K. Controlled drug delivery systems: Past forward and future back. J Control Release. 2014;190:3-8.
4
5. Bennet D, Kim S. Polymer nanoparticles for smart drug delivery. In: Sezer AD(Ed.). Application of Nanotechnology in Drug Delivery. 2014.
5
6.Das SK. Drug Delivery: Principles and Applications. AM J PHARM Educ. 2006;70(4):94.
6
7.Tiwari G, Tiwari R, Bannerjee S, Bhati L, Pandey S, Pandey P, et al. Drug delivery systems: An updated review. Int J Pharma Investig. 2012;2(1):2.
7
8.D’Souza S. A Review of In Vitro Drug Release Test Methods for Nano-Sized Dosage Forms. Advances in Pharmaceutics. 2014;2014:1-12.
8
9. Xu W. Drug release and its relationship with kinetic and thermodynamic parameters of drug sorption onto polylactide, starch acetate, wheat gluten and soy protein fibers: THE UNIVERSITY OF NEBRASKA-LINCOLN; 2009.10.Archna Panday RJ. A Review of Kinetics of Nanoparticulated Delayed Release Formulations. J Nanomed Nanotechnol. 2015;06(04).
9
10. Archna Panday RJ. A Review of Kinetics of Nanoparticulated Delayed Release Formulations. J Nanomed Nanotechnol. 2015;06(04).
10
11.Pawar P, Sharma P, Chawla A, Mehta R. Formulation and in vitro evaluation of Eudragit S-100 coated naproxen matrix tablets for colon-targeted drug delivery system. J Adv Pharm Technol Res. 2013;4(1):31.
11
12.Dash S, Murthy PN, Nath L, Chowdhury P. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm. 2010;67(3):217-23.
12
13.Chime S, Onunkwo G, Onyishi I. Kinetics and mechanisms of drug release from swellable and non swellable matrices: a review. Res J Pharm Biol Chem Sci. 2013;4(2):97-103.
13
14.Ford Versypt AN, Pack DW, Braatz RD. Mathematical modeling of drug delivery from autocatalytically degradable PLGA microspheres — A review. J Control Release. 2013;165(1):29-37.
14
15.Raval A, Parikh J, Engineer C. Mechanism of controlled release kinetics from medical devices. Braz J Chem Eng. 2010;27(2):211-25.
15
16.Sahoo C, Rao S, Sudhakar M, Satyanarayana K. The kinetic modeling of drug dissolution for drug delivery systems: An overview. Pharm Lett. 2015;7(9):186–94.
16
17.Mohammadi G, Barzegar-Jalali M, Shadbad MS, Azarmi S, Barzegar-Jalali A, Rasekhian M, et al. The effect of inorganic cations Ca2+ and Al3+ on the release rate of propranolol hydrochloride from sodium carboxymethylcellulose matrices. DARU. 2015;17(2):131-8.
17
18.Khan MA, T S. Role of Mathematical Modeling in Controlled Drug Delivery. J Sci Res. 2009;1(3).
18
19.Dash V. Release Kinetic Studies of Aspirin Microcapsules from Ethyl Cellulose, Cellulose Acetate Phthalate and their Mixtures by Emulsion Solvent Evaporation Method. Sci Pharm. 2010;78(1):93-101.
19
20.Fugit KD. Quantification of Factors Governing Drug Release Kinetics from Nanoparticles: A Combined Experimental and Mechanistic Modeling Approach [Theses and Dissertations-Pharmacy]: university of Kentacky; 2014.
20
21.Chavda HV, Patel CN. Preparation and In vitro evaluation of a stomach specific drug delivery system based on superporous hydrogel composite. Indian J Pharm Sci. 2011;73(1):30.
21
22.Frenning G. Modelling drug release from inert matrix systems: From moving-boundary to continuous-field descriptions. Int J Pharm. 2011;418(1):88-99.
22
23.Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13(2):123-33.
23
24.Mendyk A, Jachowicz R, Fijorek K, Dorożyński P, Kulinowski P, Polak S. KinetDS: An Open Source Software for Dissolution Test Data Analysis. Dissolut Technol. 2012;19(1):6-11.
24
25. Fattal E., Vauthier C. Nanoparticles as drug delivery systems. In Encyclopedia of Pharmaceutical Technology, Swarbrick J. & Boylan J. C. eds, Marcel Dekker Inc., Basel, Switzerland, 2002;1874-1892.
25
26.Hoffman AS. The origins and evolution of “controlled” drug delivery systems. J Control Release. 2008;132(3):153-63.
26
27.Jafari M, B K. Preparation and In vitro Evaluation of Isoniazid-Containing Dex-HEMA-Co-PNIPAAm Nanogels. CeN. 2015;37(1):55-62.
27
28.Jafari M, Kaffashi B. Synthesis and characterization of a novel solvent-free dextran-HEMA-PNIPAM thermosensitive nanogel. J Macromol Sci A. 2016;53(2):68-74.
28
29.Siepmann J. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Deliv Rev. 2001;48(2-3):139-57.
29
ORIGINAL_ARTICLE
Design and Characterization of Mesalamine Loaded Nanoparticles for Controlled Delivery System
Objective(s): Nanoparticles (NPs) are known for their specific accumulation in the inflamed tissues of the colon and thus allow a selective delivery to the site of inflammation with minimum adverse effects. The main objective of this work is to attain mesalamine loaded chitosan nanoparticles as a carrier for oral delivery. Methods: In this study, mesalamine loaded chitosan nanoparticles were prepared using an ionic gelation method. Experimental design Box-Behnken response surface methodology was used for the optimization of the nanoparticles. The nanoparticles size and gelation process of the polymeric nano-drug controlled release system depends on several variables including the concentration ratio of chitosan-TPP, concentration of mesalamine, concentration of chitosan solution and pH of the solution with optimum conditions of 2.3, 0.02 mg/ml, 0.1 mg/ml and 4.5, respectively. Results: The mean particle size of the synthesized nanoparticles was ranging from 53.9 to 322.8 nm using a dynamic light scattering (DLS) technique. Moreover, the morphology of the prepared nanoparticles was observed by scanning electron microscopy (SEM). Also, characterization of the chitosan-mesalamine nanoparticles was performed by FT-IR spectrophotometer for specifying the chemical structure of nanoparticles molecules and differential scanning calorimetry (DSC) for studying thermal behavior. Drug release profile and the amount of the loaded drug were also monitored by UV-Vis spectroscopy. Conclusions: Drug released showed that the release profile of mesalamine loaded nanoparticles was in a slow manner and no initial rapid release (burst effect) was illustrated.
https://www.nanomedicine-rj.com/article_21813_61dfb3e8ecf806e446bf9f8fbe177579.pdf
2016-10-01
97
106
10.7508/nmrj.2016.02.006
Chitosan
Drug delivery systems
Mesalamine
nanoparticles
Simin
Seifirad
30miin@gmail.com
1
Chemistry Department, Faculty of Science, Payame Noor University, Abhar, Iran
AUTHOR
Hasan
Karami
karami_h@yahoo.com
2
Chemistry Department, Faculty of Science, Payame Noor University, Abhar, Iran
AUTHOR
Shadab
Shahsavari
sh.shahsavari@srbiau.ac.ir
3
Chemical Engineering Department, Varamin-Pishva Branch, Islamic Azad University, Tehran, Iran
AUTHOR
Farzad
Mirabasi
farzad_mirabasi@yahoo.com
4
Chemistry Department, North Tehran Branch, Islamic Azad University, Tehran, Iran
AUTHOR
Farid
Dorkoosh
dorkoosh@tums.ac.ir
5
Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
LEAD_AUTHOR
1.Lamprecht A. Multiparticulate Systems in the Treatment of Inflammatory Bowel Disease. Curr Drug Targets Inflamm. 2003;2(2):137-44.
1
2.Hejazi R, Amiji M. Chitosan-based gastrointestinal delivery systems. J Control Release. 2003;89(2):151-65.
2
3.Chourasia MK, Jain SK. Polysaccharides for Colon Targeted Drug Delivery. Drug Deliv. 2004;11(2):129-48.
3
4.Jain SK, Jain A. Target-specific drug release to the colon. Expert Opin Drug Deliv. 2008;5(5):483-98.
4
5.Monteiro OAC, Airoldi C. Some studies of crosslinking chitosan–glutaraldehyde interaction in a homogeneous system. Int J Biol Macromolec. 1999;26(2-3):119-28.
5
6.Dodane V, Vilivalam VD. Pharmaceutical applications of chitosan. Pharm Sci Technolo Today. 1998;1(6):246-53.
6
7.Paul W, Sharma C. Chitosan, a drug carrier for the 21st century: a review. STP Pharma Sci. 2000;10(1):5-22.
7
8.Ravi Kumar MNV. A review of chitin and chitosan applications. React Funct Polym. 2000;46(1):1-27.
8
9.Gan Q, Wang T. Chitosan nanoparticle as protein delivery carrier—Systematic examination of fabrication conditions for efficient loading and release. Colloids Surf, B. 2007;59(1):24-34.
9
10.Rodrigues S, Costa AMRd, Grenha A. Chitosan/carrageenan nanoparticles: Effect of cross-linking with tripolyphosphate and charge ratios. Carbohyd Polym. 2012;89(1):282-9.
10
11.Patel MP, Patel RR, Patel JK. Chitosan Mediated Targeted Drug Delivery System: A Review. J Pharm Pharm Sci. 2010;13(4):536.
11
12.Shahsavari S, Vasheghani-Farahani E, Ardjmand M, Dorkoosh F. Design and Characterization of Acyclovir Loaded Nanoparticles for Controlled Delivery System. CURR NANOSCI. 2014;10(4):521-31.
12
13.Wold S, Sjöström M, Eriksson L. PLS-regression: a basic tool of chemometrics. Chemometr Intell Lab. 2001;58(2):109-30.
13
14.De Campos AM, Sánchez A, Alonso MaJ. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int J Pharm. 2001;224(1-2):159-68.
14
15.Devi Kusum V, Bhosale U. Formulation and optimization of polymeric nano drug delivery system of acyclovir using 3² full factorial design. Int J Pharm Technol Res. 2009;1:644-53.
15
16.Silverstein RM, Webster FX, Kiemle DJ, Bryce DL. Spectrometric identification of organic compounds. John Wiley & Sons; 2014.
16
17.Pharmacopoeia I. Ministry of health and family welfare. Government of India. 1996;2:350.
17
18.Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm. 1983;15(1):25-35.
18
19.Woitiski CB, Veiga F, Ribeiro A, Neufeld R. Design for optimization of nanoparticles integrating biomaterials for orally dosed insulin. Eur J Pharm Biopharm. 2009;73(1):25-33.
19
20.Gan Q, Wang T, Cochrane C, McCarron P. Modulation of surface charge, particle size and morphological properties of chitosan–TPP nanoparticles intended for gene delivery. Colloids Surf, B. 2005;44(2-3):65-73.
20
21.Zhang H, Oh M, Allen C, Kumacheva E. Monodisperse Chitosan Nanoparticles for Mucosal Drug Delivery. Biomacromolecules. 2004;5(6):2461-8.
21
22.Zhang H-l, Wu S-h, Tao Y, Zang L-q, Su Z-q. Preparation and Characterization of Water-Soluble Chitosan Nanoparticles as Protein Delivery System. J Nanomaterials. 2010;2010:1-5.
22
23.Ma Y, Gao H, Gu W, Yang Y-W, Wang Y, Fan Y, et al. Carboxylated poly(glycerol methacrylate)s for doxorubicin delivery. Eur J Pharm Sci. 2012;45(1-2):65-72.
23
24.Jain N, Ram A. Development and Characterization of nanostructured lipid carriers of oral hypoglycemic agent: selection of surfactants. Int J Pharm Sci Rev Res. 2011;7(2):125-30.
24
25.Seymour RW, Cooper SL. Thermal analysis of polyurethane block polymers. Macromolecules. 1973;6(1):48-53.
25
26.Tuteja A, Mackay ME, Hawker CJ, Van Horn B. Effect of Ideal, Organic Nanoparticles on the Flow Properties of Linear Polymers: Non-Einstein-like Behavior. Macromolecules. 2005;38(19):8000-11.
26
ORIGINAL_ARTICLE
Application of Electrospun Nanofibrous PHBV Scaffold in Neural Graft and Regeneration: A Mini-Review
Among the synthetic polymers, poly (3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) microbial polyester is one of the biocompatible and biodegradable copolymers in the nanomedicine scope. PHBV has key points and suitable properties to support cellular adhesion, proliferation and differentiation of nanofibers. Nanofibers are noticeably employed in order to enhance the performance of biomaterials, and could be effectively considered in this scope. Electrospinning is one of the well-known and practical methods that extremely employed in the construction of nanofibrous scaffolds for biomedical application and recently PHBV has exploited in nerve graft and regenerative medicine. PHBV composites nanofibrous scaffolds are able to be applied as promising materials in many fields, such as; wound healing and dressing, tissue engineering, targeted drug delivery systems, functional carries, biosensors or nano-biosensors and so on. In this mini-review, we attempt to provide a more detailed overview of the recent advances of PHBV electrospun nanofibers application in neural graft and regeneration.
https://www.nanomedicine-rj.com/article_21879_2007a861a754937bbc0071ba953993ba.pdf
2016-10-01
107
111
10.7508/nmrj.2016.02.007
PHBV
Electrospinning
Nanofibrous scaffolds
Neural graft
regeneration
Ali
Gheibi
aligheibi1390@gmail.com
1
Textile Engineering Department, Textile Excellence & Research Centers, Amirkabir University of Technology, Tehran, Iran
AUTHOR
Kamyar
Khoshnevisan
k-khoshnevisan@razi.tums.ac.ir
2
Biosensor Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
LEAD_AUTHOR
Najmeh
Ketabchi
najmehketabchi@yahoo.com
3
Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences
AUTHOR
Mohammad Ali
Derakhshan
m.ali_derakhshan@yahoo.com
4
Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences
AUTHOR
Arman
Babadi
arman_i06@yahoo.com
5
Nanotechnology and Catalysis Research Centre (NANOCAT), University of Malaya, IPS Building, 50603, Kuala Lumpur, Malaysia
AUTHOR
1.Gunatillake PA, Adhikari R. Biodegradable synthetic polymers for tissue engineering. Eur Cell Mater. 2003;5(1):1-16.
1
2.Vasita R, Katti DS. Nanofibers and their applications in tissue engineering. Int J Nanomedicine. 2006;1(1):15-30.
2
3.Shieh S-J, Terada S, Vacanti JP. Tissue engineering auricular reconstruction: in vitro and in vivo studies. Biomaterials. 2004;25(9):1545-57.
3
4.Aloysious N, Nair PD. Enhanced Survival and Function of Islet-Like Clusters Differentiated from Adipose Stem Cells on a Three-Dimensional Natural Polymeric Scaffold: An In Vitro Study. Tissue Eng Part A. 2014;20(9-10):1508-22.
4
5.Bhattarai SR, Bhattarai N, Yi HK, Hwang PH, Cha DI, Kim HY. Novel biodegradable electrospun membrane: scaffold for tissue engineering. Biomaterials. 2004;25(13):2595-602.
5
6.Venugopal J, Low S, Choon AT, Ramakrishna S. Interaction of cells and nanofiber scaffolds in tissue engineering. J Biomed Mater Res Part B Appl Biomater. 2008;84(1):34-48.
6
7.Bini TB, Gao S, Wang S, Ramakrishna S. Poly(l-lactide-co-glycolide) biodegradable microfibers and electrospun nanofibers for nerve tissue engineering: an in vitro study. J Mater Sci. 2006;41(19):6453-9.
7
8.Muheremu A, Ao Q. Past, Present, and Future of Nerve Conduits in the Treatment of Peripheral Nerve Injury. BioMed Res Int. 2015;2015:1-6.
8
9.Yang F, Murugan R, Wang S, Ramakrishna S. Electrospinning of nano/micro scale poly(l-lactic acid) aligned fibers and their potential in neural tissue engineering. Biomaterials. 2005;26(15):2603-10.
9
10.Rydz J, Sikorska W, Kyulavska M, Christova D. Polyester-based (bio) degradable polymers as environmentally friendly materials for sustainable development. Int J Mol Sci. 2014;16(1):564-96.
10
11.Ai J, Heidari KS, Ghorbani F, Ejazi F, Biazar E, Asefnejad A, et al. Fabrication of Coated-Collagen Electrospun PHBV Nanofiber Film by Plasma Method and Its Cellular Study. J Nanomaterials. 2011;2011:1-8.
11
12.Schnell E, Klinkhammer K, Balzer S, Brook G, Klee D, Dalton P, et al. Guidance of glial cell migration and axonal growth on electrospun nanofibers of poly-ε-caprolactone and a collagen/poly-ε-caprolactone blend. Biomaterials. 2007;28(19):3012-25.
12
13.Murugan R, Ramakrishna S. Nano-Featured Scaffolds for Tissue Engineering: A Review of Spinning Methodologies. Tissue Eng. 2006;12(3):435-47.
13
14.Yang F, Murugan R, Ramakrishna S, Wang X, Ma YX, Wang S. Fabrication of nano-structured porous PLLA scaffold intended for nerve tissue engineering. Biomaterials. 2004;25(10):1891-900.
14
15.Bini TB, Gao S, Tan TC, Wang S, Lim A, Hai LB, et al. Electrospun poly(L-lactide- co -glycolide) biodegradable polymer nanofibre tubes for peripheral nerve regeneration. Nanotechnology. 2004;15(11):1459-64.
15
16.Subramanian A, Krishnan U, Sethuraman S. Development of biomaterial scaffold for nerve tissue engineering: Biomaterial mediated neural regeneration. J Biomed Sci. 2009;16(1):108.
16
17.Panseri S, Cunha C, Lowery J, Del Carro U, Taraballi F, Amadio S, et al. Electrospun micro- and nanofiber tubes for functional nervous regeneration in sciatic nerve transections. BMC Biotechnol. 2008;8(1):39.
17
18.Wang X. Dog sciatic nerve regeneration across a 30-mm defect bridged by a chitosan/PGA artificial nerve graft. Brain. 2005;128(8):1897-910.
18
19.Majdi A, Biazar E, Heidari K. S. Fabrication and comparison of electro-spun poly hydroxy butyrate valrate nanofiber and normal film and its cellular study. Orient J Chem. 2011;27(2):523-8.
19
20.Yucel D, Kose GT, Hasirci V. Tissue Engineered, Guided Nerve Tube Consisting of Aligned Neural Stem Cells and Astrocytes. Biomacromolecules. 2010;11(12):3584-91.
20
21.Biazar E, Keshel SH. Gelatin-Modified Nanofibrous PHBV Tube as Artificial Nerve Graft for Rat Sciatic Nerve Regeneration. Int J Polym Mater Po. 2014;63(6):330-6.
21
22.Biazar E, Heidari Keshel S. A nanofibrous PHBV tube with Schwann cell as artificial nerve graft contributing to Rat sciatic nerve regeneration across a 30-mm defect bridge. Cell Commun Adhes. 2013;20(1-2):41-9.
22
23.Biazar E, Keshel SH. Chitosan–Cross-Linked Nanofibrous PHBV Nerve Guide for Rat Sciatic Nerve Regeneration Across a Defect Bridge. ASAIO J. 2013;59(6):651-9.
23
24.Keshel SH, Biazar E, Rezaei Tavirani M, Rahmati Roodsari M, Ronaghi A, Ebrahimi M, et al. The healing effect of unrestricted somatic stem cells loaded in collagen-modified nanofibrous PHBV scaffold on full-thickness skin defects. Artif Cells Nanomed Biotechnol. 2013;42(3):210-6.
24
25.Smith LA, Ma PX. Nano-fibrous scaffolds for tissue engineering. Colloids Surf, B. 2004;39(3):125-31.
25
26.Prabhakaran MP, Vatankhah E, Ramakrishna S. Electrospun aligned PHBV/collagen nanofibers as substrates for nerve tissue engineering. Biotechnol Bioeng. 2013;110(10):2775-84.
26
27.Masaeli E, Morshed M, Nasr-Esfahani MH, Sadri S, Hilderink J, van Apeldoorn A, et al. Fabrication, Characterization and Cellular Compatibility of Poly(Hydroxy Alkanoate) Composite Nanofibrous Scaffolds for Nerve Tissue Engineering. PLoS ONE. 2013;8(2):e57157.
27
ORIGINAL_ARTICLE
Drug release rate and kinetic investigation of composite polymeric nanofibers
Objective(s): In this work, electrospun nanofibers were explored as drug delivery vehicles using tetracycline as a model drug. Nanocomposite fibers including chitosan (CS)/poly (ethylene oxide) (PEO) and antibiotic were successfully prepared using electrospinning. CS blended with PEO considering a weight ratio of (90/10), and then, nanofibrous samples were successfully electrospun from their aqueous solutions. Afterwards, tetracycline was added to these samples for producing wound dressing materials. Methods: Scanning electron microscopy (SEM) and Fourier transform infrared spectroscopy (FTIR) were used for the evaluation of morphology and biodegradability studies of CS/PEO blend nanofibrous. The kinetic and drug release mechanism of drug-loaded electrospun samples were also investigated by ultraviolet-visible spectrophotometry (UV-Vis) and the appropriate model was proposed for prediction of drug release. Results: The results have indicated that the addition of tetracycline as much as 0.4%wt brings about the best nanofiber. The results of stability study of composite nanofibrous showed that the samples containing the active ingredient of tetracycline have maintained their structure after 24 h in the vicinity of acetate buffer solution. The model of antibiotic release from the nanofiber was examined and it was found that the release mechanism can be described as Fickian diffusion model. According to this model, the kinetic degree of the drug release is around 0.41. Conclusions: The study of drug release from this nanofiber showed that the liberation level is relatively high during the early hours and over time, high amounts of the drug diffuse from the inside of nanofiber into the aqueous environment.
https://www.nanomedicine-rj.com/article_22034_14b22354d48338e4f3bca2bf97f57bcc.pdf
2016-10-01
112
121
10.7508/nmrj.2016.02.008
Electrospinning
Drug release
Kinetic investigation
PEO
Tetracycline
Minoo
Sadri
mnsadri@yahoo.com
1
Department of Biochemistry and Biophysics, Education and Research Center of Science and Biotechnology, Malek Ashtar University of Technology, Tehran, Iran
LEAD_AUTHOR
Aref
Mohammadi
mr.aref.mohammadi@gmail.com
2
Department of Sciences, Rabe Rashidi University, Tabriz, Iran
AUTHOR
Hassan
Hosseini
hoseinishm@ut.ac.ir
3
Nano Research Center, Faculty of Science, Imam Hossein Comprehensive University, Tehran, Iran
AUTHOR
1.Ng EYK, Chua LT. Mesh-independent prediction of skin burns injury. J Med Eng Technol. 2000;24(6): 255-61.
1
2.Dreher F, Maibach H. Protective effects of topical antioxidants in humans. In: ThieleJJ, ElsnerP, eds. Oxidants and Antioxidants in Cutaneous Biology. Basel: Karger; 2001. p.157–164.
2
3.Kirsner RS, Eaglstein W. The wound healing process. Dermatol Clin. 1993; 11(4): 629-40.
3
4.Yoshimoto H, Shin YM, Terai H, Vacanti JP. A biodegradable nanofiber scaffold by electrospinning and its potential for bone tissue engineering. Biomaterials. 2003;24(12): 2077-82.
4
5.Shepherd R, Reader S, Falshaw A. Chitosan functional properties. Glycoconjugate j. 1997;14(4): 535-42.
5
6.Chirkov S. The antiviral activity of chitosan (review). Appl Biochem Microbiol. 2002;38(1): 1-8.
6
7.Kumar MNR. A review of chitin and chitosan applications. React Funct Polym. 2000; 46(1): 1-27.
7
8.Kong M, Chen XG, Xing K, Park HJ. Antimicrobial properties of chitosan and mode of action: A state of the art review. Int J Food Microbiol. 2010;144: 51–63.
8
9.Elsabee MZ, Naguib HF, Morsi RE. Chitosan based nanofibers, review. Mater Sci Eng. 2012; C 32:1711–26.
9
10.Antunes F, Andrade F, Sarmento B. Chitosan-Based Nanoparticulates for Oral Delivery of Biopharmaceuticals. Delivery, Targeting and Polymer Therapeutics: Wiley-Blackwell; 2012. p. 225-41.
10
11.Au HT, Pham LN, Thivu TH, Park JS. Fabrication of An Antibacterial Non-Woven Mat of a Poly (lactic acid)/Chitosan Blend by Electrospinning. Macromol Res. 2012; 20( 1): 51-8.
11
12.Berger J, Reist M, Mayer JM, Felt O, Gurny R. Structure and interactions in chitosan hydrogels formed by complexation or aggregation for biomedical applications. Eur J Pharm Biopharm. 2004; 57: 35–52.
12
13.Zhang Y, Zhang MQ. Synthesis and characterization of macroporous chitosan/calcium phosphate composite scaffolds for tissue engineering. J Biomed Mater Res. 2001; 55: 304–12.
13
14.Ji X, Yang W, Wang T, Mao C, Guo L, Xiao J, He N. Coaxially Electrospun Core/Shell Structured Poly(L-Lactide) Acid/Chitosan Nanofibers for Potential Drug Carrier in Tissue Engineering. J Biomed Nanotechnol. 2013;9: 1672-78.
14
15.Dornish M, Kaplan DS, Arepalli SR. Regulatory Status of Chitosan and Derivatives. Delivery, Targeting and Polymer Therapeutics: Wiley-Blackwell; 2012. p.463-81.
15
16.Nguyen T, Chung OH, Park JS. Coaxial electrospun poly (lactic acid)/chitosan (core/shell) composite nanofibers and their antibacterial activity. Carbohydr Polym. 2011;86:1799-806.
16
17.Tozaki H, Komoike J, Tada C, Maruyama T, Terabe A, Suzuki T, Yamamoto A, Muranishi S. Chitosan capsules for colon‐specific drug delivery: improvement of insulin absorption from the rat colon. J Pharm Sci. 1997; 86(9): 1016-21.
17
18.Shu XZ, Zhu KJ. A novel approach to prepare tripolyphosphate/chitosan complex beads for controlled release drug delivery. Int J Pharm. 2000;201(1):51-8.
18
19.Remuñán-López C, Portero A, Vila-Jato JL, Alonso MaJ. Design and evaluation of chitosan/ethylcellulose mucoadhesive bilayered devices for buccal drug delivery. J Control Release. 1998;55(2-3):143-52.
19
20.Matsunaga T, Yanagiguchi K, Yamada S, Ohara N, Ikeda T, Hayashi Y. Chitosan monomer promotes tissue regeneration on dental pulp wounds. J Biomed Mater Res A. 2006;76A(4):711-20.
20
21.Coimbra P, Alves P, Valente TAM, Santos R, Correia IJ, Ferreira P. Sodium hyaluronate/chitosan polyelectrolyte complex scaffolds for dental pulp regeneration: Synthesis and characterization. Int J Biol Macromol. 2011;49(4):573-9.
21
22.Shibasaki K, Sano H, Matsukubo T, Takaesu Y. pH response of human dental plaque to chewing gum supplemented with low molecular chitosan. Bull Tokyo Dent Coll. 1994;35(2):61-6.
22
23.MacCallum JR, Vincent CA. Polymer electrolyte reviews. Springer Science & Business Media; 1989.
23
24.Jin H-J, Fridrikh SV, Rutledge GC, Kaplan DL. Electrospinning Bombyx mori Silk with Poly(ethylene oxide). Biomacromolecules. 2002;3(6):1233-9.
24
25.Brown EE, Laborie M-PG. Bioengineering Bacterial Cellulose/Poly(ethylene oxide) Nanocomposites. Biomacromolecules. 2007;8(10):3074-81.
25
26.Daghrir R, Drogui P. Tetracycline antibiotics in the environment: a review. Environ chem lett. 2013;11(3):209-27.
26
27.Teo WE, Ramakrishna S. A review on electrospinning design and nanofibre assemblies. Nanotechnology. 2006;17(14):R89-R106.
27
28.Kazemi Pilehrood M, Dilamian M, Mirian M, Sadeghi-Aliabadi H, Maleknia L, Nousiainen P, et al. Nanofibrous Chitosan-Polyethylene Oxide Engineered Scaffolds: A Comparative Study between Simulated Structural Characteristics and Cells Viability. Biomed Res Int. 2014;2014:1-9.
28
29.Buschle-Diller G, Cooper J, Xie Z, Wu Y, Waldrup J, Ren X. Release of antibiotics from electrospun bicomponent fibers. Cellulose. 2007;14(6):553-62.
29
30.Zhang Z, Feng S-S. The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly(lactide)–tocopheryl polyethylene glycol succinate nanoparticles. Biomaterials. 2006;27(21):4025-33.
30
31.Jiang S, Lv J, Ding M, Li Y, Wang H, Jiang S. Release behavior of tetracycline hydrochloride loaded chitosan/poly(lactic acid) antimicrobial nanofibrous membranes. Mater Sci Eng C. 2016;59:86-91.
31
32.Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm. 1983;15(1):25-35.
32
33.Fu Y, Kao WJ. Drug release kinetics and transport mechanisms of non-degradable and degradable polymeric delivery systems. Expert Opin Drug Deliv. 2010;7(4):429-44.
33
34.Shah PN, Manthe RL, Lopina ST, Yun YH. Electrospinning of l-tyrosine polyurethanes for potential biomedical applications. Polymer. 2009;50(10):2281-9.
34
35.Grzybowski J. New cytokine dressings. II. Stimulation of oxidative burst in leucocytes in vitro and reduction of viable bacteria within an infected wound. Int J Pharm. 1999;184(2):179-87.
35
36.Donelli G, Francolini I, Ruggeri V, Guaglianone E, D'Ilario L, Piozzi A. Pore formers promoted release of an antifungal drug from functionalized polyurethanes to inhibit Candida colonization. J Appl Microbiol. 2006;100(3):615-22.
36
37.Simmons A, Padsalgikar AD, Ferris LM, Poole-Warren LA. Biostability and biological performance of a PDMS-based polyurethane for controlled drug release. Biomaterials. 2008;29(20):2987-95.
37